Mounjaro

What is Mounjaro?

Mounjaro is Eli Lilly’s once-weekly tirzepatide injection for type 2 diabetes. The FDA approved it in 2022, and in late 2025 the indication was extended to children aged 10 and older. Improving blood sugar is its only approved use.

What Mounjaro is not is a weight-loss drug. Weight change is a well-documented finding in its trials, but it is not an approved use, and prescribing it for weight is off-label. The weight-management version of this exact molecule is Zepbound.

It comes as a single-dose pen, a KwikPen, and a single-dose vial. Which one you have matters for storage, because their room-temperature windows differ.

Who is Mounjaro approved for?

Adults and children aged 10 and older with type 2 diabetes, alongside diet and exercise. It is not approved for type 1 diabetes, and it is not approved for weight management.

One asymmetry worth knowing if you are comparing options: no tirzepatide product carries a cardiovascular or kidney outcomes indication. Semaglutide does, under both Ozempic and Wegovy. Tirzepatide’s advantage shows up on blood sugar and weight; the outcome indications sit with the other molecule.

How does Mounjaro work?

Tirzepatide acts on the receptors for two gut hormones, GIP and GLP-1, while semaglutide acts on GLP-1 alone. That makes it a genuinely different drug rather than a stronger dose of the same one, and what GIP contributes on its own is not fully settled.

GLP-1 is a hormone your gut already releases when you eat. Activating its receptor prompts insulin release when blood sugar is high, and mainly when it is high, which is why these drugs on their own rarely cause low blood sugar. It also reduces glucagon, the signal that tells your liver to release stored sugar.

The appetite effect runs through the brain regions that handle hunger and food reward, and the weight loss that follows comes mainly from eating less rather than from burning more. Slowed stomach emptying adds to fullness and is where most of the nausea comes from; it tends to ease as your body adjusts.

That same slowdown has a consequence people are rarely warned about: it can reduce how well an oral contraceptive is absorbed. The label advises switching to a non-oral method, or adding a barrier method, for 4 weeks after starting and for 4 weeks after each dose increase. Non-oral hormonal methods are not affected.

Mounjaro for weight loss: does it work?

The honest answer needs Mounjaro’s own numbers, measured in people with type 2 diabetes at the doses this pen actually delivers. Most articles reach for the obesity trial figures instead, and those belong to Zepbound.

In the 40-week monotherapy trial, A1C fell 1.8 points at 5 mg and 1.7 points at both 10 and 15 mg, against 0.1 points on placebo. More than three quarters of people on Mounjaro reached an A1C under 7 percent, against 23 percent on placebo. Weight fell 13.9, 15.4 and 17.2 lb across the three doses, against 2.2 lb on placebo.

Notice that the blood-sugar effect is essentially flat across the three doses in that trial while the weight effect keeps climbing. Stepping up is not simply “more of everything.”

The headline weight figures that circulate under Mounjaro’s name, around 20 percent of body weight, come from the obesity trials of the same molecule sold as Zepbound, in people without diabetes and at a weight-management indication. The molecule is the same, so the results are relevant, but they are not Mounjaro’s numbers and people with type 2 diabetes lose less on the same drug.

No trial figure is the drug alone, either. Every arm received structured lifestyle support, and results varied widely between individuals.

What are the side effects of Mounjaro?

Mostly digestive, mostly early, and clustered around dose increases. Each rate below comes from the placebo-controlled diabetes trials and is shown against the placebo rate in the same trials, because the raw figure alone overstates what the drug adds. Diarrhea is the clearest case: 12 to 17 percent looks alarming until you see 9 percent on placebo.

These are diabetes-dose figures in a diabetes population. They are not comparable to Zepbound’s, which come from obesity trials at different doses, and no label permits ranking one drug against another this way.

On the eyes, tirzepatide’s label differs from semaglutide’s in a way worth stating precisely. Semaglutide’s carries a retinopathy finding with numbers behind it. Tirzepatide’s says the drug has not been studied in proliferative retinopathy, retinopathy needing acute treatment, or macular edema, and advises monitoring people with a history of retinopathy. That is an absence of data rather than a signal.

Anti-drug antibodies are common on tirzepatide, in about half of people in the adult trials. The label reports no identified clinically significant effect on how the drug behaves in the body or on how well it works, and separately that antibody-positive patients had more hypersensitivity and injection-site reactions. Those are two findings, not one, and antibody rates cannot be compared across drugs because the assays differ.

Because the drug slows stomach emptying, the label instructs patients to tell their care team before any procedure requiring general anesthesia or deep sedation. There is also a small increase in resting heart rate.

One point of reassurance that is often reported wrong: Mounjaro never carried the suicidality warning. That warning existed on three products and was removed from all of them in February 2026 after FDA reviewed the question. Mounjaro was not among them. Ordinary vigilance still applies, so tell your prescriber about new or worsening mood changes.

Practical management, which rests on clinical experience rather than trials of the advice itself: smaller meals, less fatty food and alcohol around injection day, and enough fluid. Persistent severe abdominal pain is not a symptom to wait out.

Who should not take Mounjaro?

The label lists exactly two contraindications. The rest are worth raising with your prescriber before you start.

The boxed warning drives the first: because tirzepatide caused thyroid C-cell tumors in rats, anyone with a personal or family history of medullary thyroid cancer, or with MEN 2, should not take it. The second is a serious hypersensitivity reaction to tirzepatide or any ingredient.

Mounjaro dosage: schedule and strengths

Everyone starts at 2.5 mg once weekly for four weeks, then moves to 5 mg. After that, the dose can rise in 2.5 mg increments, each after at least four weeks, if more glycemic control is needed.

Two things worth knowing. The starting dose is exactly that: the label does not present 2.5 mg as a treatment dose for blood sugar. And the maximum differs by age: 15 mg once weekly for adults, but 10 mg for children aged 10 and older. Adult figures do not carry over to the pediatric indication, which has its own trial.

Missed a dose? Mounjaro’s label says to take it as soon as possible within 4 days (96 hours). That window is specific to tirzepatide: Ozempic’s label says 5 days, and the daily tablets say to skip the dose entirely.

How do you use the Mounjaro pen?

Mounjaro comes in three presentations that do not operate identically. The steps below are a summary. Follow the Instructions for Use for your exact product, and ask your pharmacist or prescriber to walk you through it the first time.

1. Check the medicine and the device as your Instructions for Use direct.
2. Inject under the skin of the abdomen or thigh. These are the two sites you use on yourself.
3. The upper arm is different on tirzepatide. Both the Mounjaro and Zepbound labels direct that another person give the injection in the back of the upper arm. This is not true of every GLP-1, and it is the most commonly repeated error about this drug.
4. Use a different spot within the area each week. The label instructs rotation and gives no reason for it.
5. If you also take insulin, they go in as separate injections, never mixed in one syringe. They can go in the same body area, but not the same spot. Only two of the seven products in this class carry that instruction, and Mounjaro is one of them.
6. Dispose of needles in a sharps container, and never share a KwikPen with another person even with a new needle.

Storage depends on the presentation, and the windows really are different. Single-dose pens and single-dose vials are refrigerated, and may be kept unrefrigerated up to 86°F for a total of 21 days. The KwikPen and multi-dose vial get 30 days.

How much does Mounjaro cost?

What you pay depends less on the pharmacy than on your diagnosis. The figures below move often, so confirm them before acting.

The diagnosis asterisk, spelled out: most commercial plans and Medicare Part D cover Mounjaro for type 2 diabetes. Prescribed off-label for weight, coverage usually disappears, because insurers check the diagnosis code. Coverage for obesity treatment generally is a patchwork, and where it exists it often comes with prior authorization or a lifestyle-program requirement. If weight is the goal, pursuing Zepbound coverage is usually the more direct route.

There is no FDA-approved generic tirzepatide. Compounded tirzepatide occupies a narrower legal space than it did during the shortage, which we cover in the tirzepatide guide.

Mounjaro vs Zepbound, Ozempic, and Wegovy

Mounjaro vs Zepbound

Same molecule, different products. Mounjaro is approved for type 2 diabetes, in adults and children 10 and up. Zepbound is approved for weight management and obstructive sleep apnea, in adults only. If weight is the goal and you do not have diabetes, Zepbound is the one with the matching label. About Zepbound →

Mounjaro vs Ozempic

The one direct comparison. In a randomized diabetes trial, tirzepatide lowered both blood sugar and weight more than semaglutide at every dose tested, with roughly 1.9 to 5.5 kg of extra weight loss depending on dose. The caveat matters: semaglutide was capped at 1 mg, which was Ozempic’s maximum at the time but below what is approved today, so this is not a maximum-versus-maximum comparison. At 5 mg, tirzepatide did not beat semaglutide on the share of people reaching an A1C under 7 percent. Ozempic also carries cardiovascular and kidney outcome indications that no tirzepatide product has. About Ozempic →

Mounjaro vs Wegovy

A cross-category matchup: Wegovy is semaglutide approved for weight management, so its real counterpart is Zepbound rather than Mounjaro. Wegovy also carries a cardiovascular outcomes indication. About Wegovy →

Looking beyond the brand? See every Mounjaro alternative →

How to get Mounjaro

Mounjaro is prescription-only. A licensed provider has to write it, whether for diabetes or off-label, and sites promising it without a prescription are not selling the approved product. Three legitimate paths:

Mounjaro myths and misconceptions

Five claims we hear constantly, and what is actually true.

• Myth Mounjaro is FDA-approved for weight loss.

  It is approved to improve blood sugar in type 2 diabetes, and that is its only indication. The weight-management approval belongs to Zepbound, the same molecule under a different name.

• Myth Mounjaro is just a stronger Ozempic.

  It is a different molecule. Tirzepatide acts on two gut-hormone receptors, GIP and GLP-1; semaglutide acts on one. Different drug, different maker, not a higher dose of the same thing.

• Myth Because it beat semaglutide in a trial, it is simply the better drug.

  That trial capped semaglutide at 1 mg, below the doses approved today, so it was not a maximum-versus-maximum comparison. Tirzepatide also has no cardiovascular or kidney outcomes indication under either brand name, while semaglutide does.

• Myth The thyroid warning means these drugs cause thyroid cancer.

  The boxed warning comes from rat studies. Every label in the class says the same thing, that whether it happens in humans has not been determined. It is still a contraindication if you or a family member has had medullary thyroid cancer or MEN 2.

• Myth Compounded tirzepatide is the same as Mounjaro.

  Compounded versions are not FDA-approved products, and their dose and purity are not reviewed the way an approved product's are.